Eli Lilly (LLY) announced positive results from the Phase 3 ATTAIN-2 trial for orforglipron, a potential treatment for obesity and type 2 diabetes, achieving key endpoints such as significant weight loss. Additionally, a clinical supply agreement with Immuneering for olomorasib, targeting lung cancer, marks continued innovation. Despite these promising advancements, LLY traded flat over the last week, aligning with broader market trends, as the overall market performance remained steady. These company developments, while significant, coincided with President Trump's actions concerning the Federal Reserve, which have stirred broader economic considerations.

Eli Lilly's recent achievements with the ATTAIN-2 trial and the clinical supply agreement signify strong potential for revenue and earnings growth. Positive trial outcomes for obesity and type 2 diabetes treatments like orforglipron may bolster future revenue streams, augmenting the projected annual revenue growth rate of 14%. Additionally, the agreement with Immuneering could enhance Eli Lilly's innovative capacity in the oncology space, potentially boosting its forecast earnings growth of 21.2% annually over the next three years.

Over the past five years, Eli Lilly's total shareholder return, encompassing both share price appreciation and dividends, surged by a very large 399.25%. Despite the impressive long-term performance, the stock dipped 14.6% over the past year, underperforming relative to the broader US Pharmaceuticals industry. This historical context shows the company’s strong track record over the longer term, though recent market dynamics have posed some challenges.

With the current share price at US$695.33, a significant gap remains to the consensus analyst price target of US$887.60. This target reflects expectations of robust growth driven by advancements in key drug segments and manufacturing expansions. Analysts project revenue could reach US$88.9 billion and earnings could hit US$34 billion by 2028 if these growth drivers materialize. However, as analysts have varying perspectives, it's important for investors to evaluate these projections within the broader market context.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.